{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,21]],"date-time":"2026-06-21T06:27:26Z","timestamp":1782023246382,"version":"3.54.5"},"reference-count":88,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T00:00:00Z","timestamp":1745539200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T00:00:00Z","timestamp":1745539200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s11033-025-10536-w","type":"journal-article","created":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T03:46:41Z","timestamp":1745552801000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["CHD1 dysregulation in cancer: bridging chromatin instability, therapy resistance, and immune evasion"],"prefix":"10.1007","volume":"52","author":[{"given":"K. S. Praveen","family":"Kumar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. N.","family":"Jyothi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akila","family":"Prashant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,25]]},"reference":[{"key":"10536_CR1","doi-asserted-by":"publisher","first-page":"a026450","DOI":"10.1101\/cshperspect.a026450","volume":"7","author":"AA Mills","year":"2017","unstructured":"Mills AA (2017) The chromodomain helicase DNA-Binding chromatin remodelers: family traits that protect from and promote Cancer. Cold Spring Harb Perspect Med 7:a026450. https:\/\/doi.org\/10.1101\/cshperspect.a026450","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10536_CR2","doi-asserted-by":"publisher","first-page":"8929","DOI":"10.1038\/s41598-019-45263-3","volume":"9","author":"A Boginya","year":"2019","unstructured":"Boginya A, Detroja R, Matityahu A et al (2019) The chromatin remodeler Chd1 regulates cohesin in budding yeast and humans. Sci Rep 9:8929. https:\/\/doi.org\/10.1038\/s41598-019-45263-3","journal-title":"Sci Rep"},{"key":"10536_CR3","doi-asserted-by":"publisher","first-page":"2596","DOI":"10.1038\/emboj.2011.166","volume":"30","author":"DP Ryan","year":"2011","unstructured":"Ryan DP, Sundaramoorthy R, Martin D et al (2011) The DNA-binding domain of the Chd1 chromatin-remodelling enzyme contains SANT and SLIDE domains. EMBO J 30:2596\u20132609. https:\/\/doi.org\/10.1038\/emboj.2011.166","journal-title":"EMBO J"},{"key":"10536_CR4","doi-asserted-by":"publisher","first-page":"1123362","DOI":"10.3389\/fonc.2023.1123362","volume":"13","author":"H Li","year":"2023","unstructured":"Li H, Gigi L, Zhao D (2023) CHD1, a multifaceted epigenetic remodeler in prostate cancer. Front Oncol 13:1123362. https:\/\/doi.org\/10.3389\/fonc.2023.1123362","journal-title":"Front Oncol"},{"key":"10536_CR5","doi-asserted-by":"publisher","first-page":"215619","DOI":"10.1016\/j.canlet.2022.215619","volume":"534","author":"F Fontana","year":"2022","unstructured":"Fontana F, Anselmi M, Limonta P (2022) Molecular mechanisms and genetic alterations in prostate cancer: from diagnosis to targeted therapy. Cancer Lett 534:215619. https:\/\/doi.org\/10.1016\/j.canlet.2022.215619","journal-title":"Cancer Lett"},{"key":"10536_CR6","doi-asserted-by":"publisher","first-page":"2795","DOI":"10.1158\/0008-5472.CAN-12-1342","volume":"73","author":"L Burkhardt","year":"2013","unstructured":"Burkhardt L, Fuchs S, Krohn A et al (2013) CHD1 is a 5q21 tumor suppressor required for ERG rearrangement in prostate Cancer. Cancer Res 73:2795\u20132805. https:\/\/doi.org\/10.1158\/0008-5472.CAN-12-1342","journal-title":"Cancer Res"},{"key":"10536_CR7","doi-asserted-by":"publisher","first-page":"2781","DOI":"10.1111\/cas.14935","volume":"112","author":"K Okasho","year":"2021","unstructured":"Okasho K, Mizuno K, Fukui T et al (2021) Establishment and characterization of a novel treatment-related neuroendocrine prostate cancer cell line KUCaP13. Cancer Sci 112:2781\u20132791. https:\/\/doi.org\/10.1111\/cas.14935","journal-title":"Cancer Sci"},{"key":"10536_CR8","doi-asserted-by":"publisher","first-page":"2511","DOI":"10.1016\/j.gendis.2022.12.015","volume":"10","author":"A Ertay","year":"2023","unstructured":"Ertay A, Ewing RM, Wang Y (2023) Synthetic lethal approaches to target cancers with loss of PTEN function. Genes Dis 10:2511\u20132527. https:\/\/doi.org\/10.1016\/j.gendis.2022.12.015","journal-title":"Genes Dis"},{"key":"10536_CR9","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1093\/annonc\/mdx165","volume":"28","author":"TR Shenoy","year":"2017","unstructured":"Shenoy TR, Boysen G, Wang MY et al (2017) CHD1 loss sensitizes prostate cancer to DNA damaging therapy by promoting error-prone double-strand break repair. Ann Oncol 28:1495\u20131507. https:\/\/doi.org\/10.1093\/annonc\/mdx165","journal-title":"Ann Oncol"},{"key":"10536_CR10","doi-asserted-by":"publisher","first-page":"3891","DOI":"10.1093\/nar\/gky128","volume":"46","author":"J Zhou","year":"2018","unstructured":"Zhou J, Li J, Serafim RB et al (2018) Human CHD1 is required for early DNA-damage signaling and is uniquely regulated by its N terminus. Nucleic Acids Res 46:3891\u20133905. https:\/\/doi.org\/10.1093\/nar\/gky128","journal-title":"Nucleic Acids Res"},{"key":"10536_CR11","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1101\/gad.348897.121","volume":"35","author":"A Alendar","year":"2021","unstructured":"Alendar A, Berns A (2021) Sentinels of chromatin: chromodomain helicase DNA-binding proteins in development and disease. Genes Dev 35:1403\u20131430. https:\/\/doi.org\/10.1101\/gad.348897.121","journal-title":"Genes Dev"},{"key":"10536_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41392-023-01480-x","volume":"8","author":"J Yang","year":"2023","unstructured":"Yang J, Xu J, Wang W et al (2023) Epigenetic regulation in the tumor microenvironment: molecular mechanisms and therapeutic targets. Signal Transduct Target Ther 8:1\u201326. https:\/\/doi.org\/10.1038\/s41392-023-01480-x","journal-title":"Signal Transduct Target Ther"},{"key":"10536_CR13","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/1756-8935-7-32","volume":"7","author":"D Park","year":"2014","unstructured":"Park D, Shivram H, Iyer VR (2014) Chd1 co-localizes with early transcription elongation factors independently of H3K36 methylation and releases stalled RNA polymerase II at introns. Epigenetics Chromatin 7:32. https:\/\/doi.org\/10.1186\/1756-8935-7-32","journal-title":"Epigenetics Chromatin"},{"key":"10536_CR14","doi-asserted-by":"publisher","first-page":"zcaa018","DOI":"10.1093\/narcan\/zcaa018","volume":"2","author":"EH Kim","year":"2020","unstructured":"Kim EH, Cao D, Mahajan NP et al (2020) ACK1-AR and AR-HOXB13 signaling axes: epigenetic regulation of lethal prostate cancers. NAR Cancer 2:zcaa018. https:\/\/doi.org\/10.1093\/narcan\/zcaa018","journal-title":"NAR Cancer"},{"key":"10536_CR15","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1186\/s12943-024-02069-w","volume":"23","author":"S Kiri","year":"2024","unstructured":"Kiri S, Ryba T (2024) Cancer, metastasis, and the epigenome. Mol Cancer 23:154. https:\/\/doi.org\/10.1186\/s12943-024-02069-w","journal-title":"Mol Cancer"},{"key":"10536_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41392-022-01042-7","volume":"7","author":"Y He","year":"2022","unstructured":"He Y, Xu W, Xiao Y-T et al (2022) Targeting signaling pathways in prostate cancer: mechanisms and clinical trials. Signal Transduct Target Ther 7:1\u201331. https:\/\/doi.org\/10.1038\/s41392-022-01042-7","journal-title":"Signal Transduct Target Ther"},{"key":"10536_CR17","doi-asserted-by":"publisher","unstructured":"Soltan MA, Eldeen MA, Eid RA et al (2023) A pan-cancer analysis reveals CHD1L as a prognostic and immunological biomarker in several human cancers. Front Mol Biosci 10. https:\/\/doi.org\/10.3389\/fmolb.2023.1017148","DOI":"10.3389\/fmolb.2023.1017148"},{"key":"10536_CR18","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/j.ccell.2019.03.001","volume":"35","author":"MA Augello","year":"2019","unstructured":"Augello MA, Liu D, Deonarine LD et al (2019) CHD1 loss alters AR binding at Lineage-Specific enhancers and modulates distinct transcriptional programs to drive prostate tumorigenesis. Cancer Cell 35:603\u2013617e8. https:\/\/doi.org\/10.1016\/j.ccell.2019.03.001","journal-title":"Cancer Cell"},{"key":"10536_CR19","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/nrurol.2018.9","volume":"15","author":"T Jamaspishvili","year":"2018","unstructured":"Jamaspishvili T, Berman DM, Ross AE et al (2018) Clinical implications of PTEN loss in prostate cancer. Nat Rev Urol 15:222\u2013234. https:\/\/doi.org\/10.1038\/nrurol.2018.9","journal-title":"Nat Rev Urol"},{"key":"10536_CR20","doi-asserted-by":"publisher","first-page":"1970","DOI":"10.1038\/s41401-020-00604-1","volume":"42","author":"Y Chen","year":"2021","unstructured":"Chen Y, Tan L, Gong J et al (2021) Response prediction biomarkers and drug combinations of PARP inhibitors in prostate cancer. Acta Pharmacol Sin 42:1970\u20131980. https:\/\/doi.org\/10.1038\/s41401-020-00604-1","journal-title":"Acta Pharmacol Sin"},{"key":"10536_CR21","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/j.ccell.2020.03.001","volume":"37","author":"Z Zhang","year":"2020","unstructured":"Zhang Z, Zhou C, Li X et al (2020) Loss of CHD1 promotes heterogeneous mechanisms of resistance to AR-Targeted therapy via chromatin dysregulation. Cancer Cell 37:584\u2013598e11. https:\/\/doi.org\/10.1016\/j.ccell.2020.03.001","journal-title":"Cancer Cell"},{"key":"10536_CR22","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s13045-024-01551-8","volume":"17","author":"M-Q Shi","year":"2024","unstructured":"Shi M-Q, Xu Y, Fu X et al (2024) Advances in targeting histone deacetylase for treatment of solid tumors. J Hematol OncolJ Hematol Oncol 17:37. https:\/\/doi.org\/10.1186\/s13045-024-01551-8","journal-title":"J Hematol OncolJ Hematol Oncol"},{"key":"10536_CR23","doi-asserted-by":"publisher","first-page":"FSO372","DOI":"10.4155\/fsoa-2018-0115","volume":"5","author":"A Alqahtani","year":"2019","unstructured":"Alqahtani A, Choucair K, Ashraf M et al (2019) Bromodomain and extra-terminal motif inhibitors: a review of preclinical and clinical advances in cancer therapy. Future Sci OA 5:FSO372. https:\/\/doi.org\/10.4155\/fsoa-2018-0115","journal-title":"Future Sci OA"},{"key":"10536_CR24","doi-asserted-by":"publisher","first-page":"e59","DOI":"10.1002\/mog2.59","volume":"3","author":"L Tao","year":"2024","unstructured":"Tao L, Zhou Y, Luo Y et al (2024) Epigenetic regulation in cancer therapy: from mechanisms to clinical advances. MedComm\u2013 Oncol 3:e59. https:\/\/doi.org\/10.1002\/mog2.59","journal-title":"MedComm\u2013 Oncol"},{"key":"10536_CR25","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s13619-024-00203-z","volume":"13","author":"X Li","year":"2024","unstructured":"Li X, Zhu G, Zhao B (2024) Chromatin remodeling in tissue stem cell fate determination. Cell Regen 13:18. https:\/\/doi.org\/10.1186\/s13619-024-00203-z","journal-title":"Cell Regen"},{"key":"10536_CR26","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1097\/MOH.0000000000000710","volume":"29","author":"Z Tu","year":"2022","unstructured":"Tu Z, Zheng Y (2022) Role of ATP-dependent chromatin remodelers in hematopoietic stem and progenitor cell maintenance. Curr Opin Hematol 29:174\u2013180. https:\/\/doi.org\/10.1097\/MOH.0000000000000710","journal-title":"Curr Opin Hematol"},{"key":"10536_CR27","doi-asserted-by":"publisher","unstructured":"Schoberleitner I, Mutti A, Sah A et al (2019) Role for chromatin remodeling factor Chd1 in learning and memory. Front Mol Neurosci 12. https:\/\/doi.org\/10.3389\/fnmol.2019.00003","DOI":"10.3389\/fnmol.2019.00003"},{"key":"10536_CR28","doi-asserted-by":"crossref","unstructured":"Alendar A (2023) Rise of the Chromodomain Helicase DNA-Binding (CHD) Chromatin Remodelling Machines. pp 1\u201332","DOI":"10.1002\/9780470015902.a0029448"},{"key":"10536_CR29","doi-asserted-by":"publisher","first-page":"4978","DOI":"10.1093\/nar\/gky206","volume":"46","author":"JM Tokuda","year":"2018","unstructured":"Tokuda JM, Ren R, Levendosky RF et al (2018) The ATPase motor of the Chd1 chromatin remodeler stimulates DNA unwrapping from the nucleosome. Nucleic Acids Res 46:4978\u20134990. https:\/\/doi.org\/10.1093\/nar\/gky206","journal-title":"Nucleic Acids Res"},{"key":"10536_CR30","doi-asserted-by":"publisher","first-page":"e56178","DOI":"10.7554\/eLife.56178","volume":"9","author":"L Farnung","year":"2020","unstructured":"Farnung L, Ochmann M, Cramer P (2020) Nucleosome-CHD4 chromatin remodeler structure maps human disease mutations. eLife 9:e56178. https:\/\/doi.org\/10.7554\/eLife.56178","journal-title":"eLife"},{"key":"10536_CR31","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1038\/s41585-021-00442-8","volume":"18","author":"Y Zhu","year":"2021","unstructured":"Zhu Y, Mo M, Wei Y et al (2021) Epidemiology and genomics of prostate cancer in Asian men. Nat Rev Urol 18:282\u2013301. https:\/\/doi.org\/10.1038\/s41585-021-00442-8","journal-title":"Nat Rev Urol"},{"key":"10536_CR32","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/s41586-020-2135-x","volume":"580","author":"J Li","year":"2020","unstructured":"Li J, Xu C, Lee HJ et al (2020) A genomic and epigenomic atlas of prostate cancer in Asian populations. Nature 580:93\u201399. https:\/\/doi.org\/10.1038\/s41586-020-2135-x","journal-title":"Nature"},{"key":"10536_CR33","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.molcel.2017.08.018","volume":"68","author":"Y Qiu","year":"2017","unstructured":"Qiu Y, Levendosky RF, Chakravarthy S et al (2017) The Chd1 chromatin remodeler shifts nucleosomal DNA bidirectionally as a monomer. Mol Cell 68:76\u201388e6. https:\/\/doi.org\/10.1016\/j.molcel.2017.08.018","journal-title":"Mol Cell"},{"key":"10536_CR34","doi-asserted-by":"publisher","first-page":"4625","DOI":"10.1093\/nar\/gkw068","volume":"44","author":"J Ocampo","year":"2016","unstructured":"Ocampo J, Chereji RV, Eriksson PR, Clark DJ (2016) The ISW1 and CHD1 ATP-dependent chromatin remodelers compete to set nucleosome spacing in vivo. Nucleic Acids Res 44:4625\u20134635. https:\/\/doi.org\/10.1093\/nar\/gkw068","journal-title":"Nucleic Acids Res"},{"key":"10536_CR35","doi-asserted-by":"publisher","first-page":"7722","DOI":"10.1093\/nar\/gkx377","volume":"45","author":"SJ Baumgart","year":"2017","unstructured":"Baumgart SJ, Najafova Z, Hossan T et al (2017) CHD1 regulates cell fate determination by activation of differentiation-induced genes. Nucleic Acids Res 45:7722\u20137735. https:\/\/doi.org\/10.1093\/nar\/gkx377","journal-title":"Nucleic Acids Res"},{"key":"10536_CR36","doi-asserted-by":"publisher","first-page":"710203","DOI":"10.3389\/fcell.2021.710203","volume":"9","author":"C Liu","year":"2021","unstructured":"Liu C, Kang N, Guo Y, Gong P (2021) Advances in chromodomain helicase DNA-Binding (CHD) proteins regulating stem cell differentiation and human diseases. Front Cell Dev Biol 9:710203. https:\/\/doi.org\/10.3389\/fcell.2021.710203","journal-title":"Front Cell Dev Biol"},{"key":"10536_CR37","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/S0006-291X(03)01354-8","volume":"308","author":"H Tai","year":"2003","unstructured":"Tai H, Geisterfer M, Bell J et al (2003) CHD1 associates with NCoR and histone deacetylase as well as with RNA splicing proteins. Biochem Biophys Res Commun 308:170\u2013176. https:\/\/doi.org\/10.1016\/S0006-291X(03)01354-8","journal-title":"Biochem Biophys Res Commun"},{"key":"10536_CR38","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/j.ccell.2020.03.001","volume":"37","author":"Z Zhang","year":"2020","unstructured":"Zhang Z, Zhou C, Li X et al (2020) Loss of CHD1 promotes heterogeneous mechanisms of resistance to AR-Targeted therapy via chromatin dysregulation. Cancer Cell 37:584\u2013598e11. https:\/\/doi.org\/10.1016\/j.ccell.2020.03.001","journal-title":"Cancer Cell"},{"key":"10536_CR39","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1158\/2159-8290.CD-19-1352","volume":"10","author":"D Zhao","year":"2020","unstructured":"Zhao D, Cai L, Lu X et al (2020) Chromatin regulator CHD1 remodels the immunosuppressive tumor microenvironment in PTEN-Deficient prostate Cancer. Cancer Discov 10:1374\u20131387. https:\/\/doi.org\/10.1158\/2159-8290.CD-19-1352","journal-title":"Cancer Discov"},{"key":"10536_CR40","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1002\/pros.24218","volume":"81","author":"S Hern\u00e1ndez-Llodr\u00e0","year":"2021","unstructured":"Hern\u00e1ndez-Llodr\u00e0 S, Segal\u00e9s L, Juanpere N et al (2021) SPOP and CHD1 alterations in prostate cancer: relationship with PTEN loss, tumor grade, perineural infiltration, and PSA recurrence. Prostate 81:1267\u20131277. https:\/\/doi.org\/10.1002\/pros.24218","journal-title":"Prostate"},{"key":"10536_CR41","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1016\/j.jmoldx.2020.07.003","volume":"22","author":"W Ebrahimizadeh","year":"2020","unstructured":"Ebrahimizadeh W, Gu\u00e9rard K-P, Rouzbeh S et al (2020) Design and development of a fully synthetic multiplex Ligation-Dependent probe Amplification-Based probe mix for detection of copy number alterations in prostate Cancer Formalin-Fixed, Paraffin-Embedded tissue samples. J Mol Diagn JMD 22:1246\u20131263. https:\/\/doi.org\/10.1016\/j.jmoldx.2020.07.003","journal-title":"J Mol Diagn JMD"},{"key":"10536_CR42","doi-asserted-by":"publisher","first-page":"2595","DOI":"10.1158\/1078-0432.CCR-19-1669","volume":"26","author":"FA Faisal","year":"2020","unstructured":"Faisal FA, Murali S, Kaur H et al (2020) CDKN1B deletions are associated with metastasis in African American men with clinically localized, surgically treated prostate Cancer. Clin Cancer Res Off J Am Assoc Cancer Res 26:2595\u20132602. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-1669","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"10536_CR43","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1158\/1541-7786.MCR-20-0975","volume":"19","author":"S Gupta","year":"2021","unstructured":"Gupta S, Halabi S, Kemeny G et al (2021) Circulating tumor cell genomic evolution and hormone therapy outcomes in men with metastatic Castration-Resistant prostate Cancer. Mol Cancer Res MCR 19:1040\u20131050. https:\/\/doi.org\/10.1158\/1541-7786.MCR-20-0975","journal-title":"Mol Cancer Res MCR"},{"key":"10536_CR44","doi-asserted-by":"publisher","first-page":"bqad100","DOI":"10.1210\/endocr\/bqad100","volume":"164","author":"JR Bobbitt","year":"2023","unstructured":"Bobbitt JR, Seachrist DD, Keri RA (2023) Chromatin organization and transcriptional programming of breast Cancer cell identity. Endocrinology 164:bqad100. https:\/\/doi.org\/10.1210\/endocr\/bqad100","journal-title":"Endocrinology"},{"key":"10536_CR45","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1038\/nature21357","volume":"542","author":"D Zhao","year":"2017","unstructured":"Zhao D, Lu X, Wang G et al (2017) Synthetic essentiality of chromatin remodelling factor CHD1 in PTEN-deficient cancer. Nature 542:484\u2013488. https:\/\/doi.org\/10.1038\/nature21357","journal-title":"Nature"},{"key":"10536_CR46","doi-asserted-by":"publisher","first-page":"82","DOI":"10.3390\/medicines6030082","volume":"6","author":"U Testa","year":"2019","unstructured":"Testa U, Castelli G, Pelosi E (2019) Cellular and molecular mechanisms underlying prostate Cancer development: therapeutic implications. Medicines 6:82. https:\/\/doi.org\/10.3390\/medicines6030082","journal-title":"Medicines"},{"key":"10536_CR47","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1002\/pros.24080","volume":"81","author":"Y Zhu","year":"2021","unstructured":"Zhu Y, Wen J, Huang G et al (2021) CHD1 and SPOP synergistically protect prostate epithelial cells from DNA damage. Prostate 81:81\u201388. https:\/\/doi.org\/10.1002\/pros.24080","journal-title":"Prostate"},{"key":"10536_CR48","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1101\/gad.315739.118","volume":"32","author":"G Wang","year":"2018","unstructured":"Wang G, Zhao D, Spring DJ, DePinho RA (2018) Genetics and biology of prostate cancer. Genes Dev 32:1105\u20131140. https:\/\/doi.org\/10.1101\/gad.315739.118","journal-title":"Genes Dev"},{"key":"10536_CR49","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1158\/1541-7786.MCR-18-1335","volume":"17","author":"S Washino","year":"2019","unstructured":"Washino S, Rider LC, Romero L et al (2019) Loss of MAP3K7 sensitizes prostate Cancer cells to CDK1\/2 Inhibition and DNA damage by disrupting homologous recombination. Mol Cancer Res MCR 17:1985\u20131998. https:\/\/doi.org\/10.1158\/1541-7786.MCR-18-1335","journal-title":"Mol Cancer Res MCR"},{"key":"10536_CR50","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/s41417-020-00288-z","volume":"29","author":"SJ Oh-Hohenhorst","year":"2022","unstructured":"Oh-Hohenhorst SJ, Tilki D, Ahlers A-K et al (2022) CHD1 loss negatively influences metastasis-free survival in R0-resected prostate cancer patients and promotes spontaneous metastasis in vivo. Cancer Gene Ther 29:49\u201361. https:\/\/doi.org\/10.1038\/s41417-020-00288-z","journal-title":"Cancer Gene Ther"},{"key":"10536_CR51","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/j.bbrc.2020.02.136","volume":"525","author":"S Rahmy","year":"2020","unstructured":"Rahmy S, Cheng X, Wang M et al (2020) Organ-specific regulation of CHD1 by acute PTEN and p53 loss in mice. Biochem Biophys Res Commun 525:614\u2013619. https:\/\/doi.org\/10.1016\/j.bbrc.2020.02.136","journal-title":"Biochem Biophys Res Commun"},{"key":"10536_CR52","doi-asserted-by":"publisher","first-page":"175628722110224","DOI":"10.1177\/17562872211022462","volume":"13","author":"A Kareddula","year":"2021","unstructured":"Kareddula A, Medina DJ, Petrosky W et al (2021) The role of chromodomain helicase DNA binding protein 1 (CHD1) in promoting an invasive prostate cancer phenotype. Ther Adv Urol 13:17562872211022462. https:\/\/doi.org\/10.1177\/17562872211022462","journal-title":"Ther Adv Urol"},{"key":"10536_CR53","doi-asserted-by":"publisher","first-page":"152","DOI":"10.4103\/aja202287","volume":"25","author":"Y-Z Wang","year":"2023","unstructured":"Wang Y-Z, Qian Y-C, Yang W-J et al (2023) CHD1 deletion stabilizes HIF1\u03b1 to promote angiogenesis and Glycolysis in prostate cancer. Asian J Androl 25:152\u2013157. https:\/\/doi.org\/10.4103\/aja202287","journal-title":"Asian J Androl"},{"key":"10536_CR54","doi-asserted-by":"publisher","first-page":"12355","DOI":"10.1038\/s41598-023-39626-0","volume":"13","author":"S Takahashi","year":"2023","unstructured":"Takahashi S, Takada I, Hashimoto K et al (2023) ESS2 controls prostate cancer progression through recruitment of chromodomain helicase DNA binding protein 1. Sci Rep 13:12355. https:\/\/doi.org\/10.1038\/s41598-023-39626-0","journal-title":"Sci Rep"},{"key":"10536_CR55","doi-asserted-by":"publisher","first-page":"435","DOI":"10.3390\/jcm8040435","volume":"8","author":"MYT Keung","year":"2019","unstructured":"Keung MYT, Wu Y, Vadgama JV (2019) PARP inhibitors as a therapeutic agent for homologous recombination deficiency in breast cancers. J Clin Med 8:435. https:\/\/doi.org\/10.3390\/jcm8040435","journal-title":"J Clin Med"},{"key":"10536_CR56","doi-asserted-by":"publisher","first-page":"108610","DOI":"10.1016\/j.pharmthera.2024.108610","volume":"256","author":"M Zhang","year":"2024","unstructured":"Zhang M, Wu K, Zhang W et al (2024) The therapeutic potential of targeting the CHD protein family in cancer. Pharmacol Ther 256:108610. https:\/\/doi.org\/10.1016\/j.pharmthera.2024.108610","journal-title":"Pharmacol Ther"},{"key":"10536_CR57","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.omto.2020.05.004","volume":"17","author":"RS Bayne","year":"2020","unstructured":"Bayne RS, Puckett S, Rodrigues LU et al (2020) MAP3K7 and CHD1 are novel mediators of resistance to oncolytic vesicular stomatitis virus in prostate Cancer cells. Mol Ther Oncolytics 17:496\u2013507. https:\/\/doi.org\/10.1016\/j.omto.2020.05.004","journal-title":"Mol Ther Oncolytics"},{"key":"10536_CR58","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.15252\/embr.201642352","volume":"17","author":"V Kari","year":"2016","unstructured":"Kari V, Mansour WY, Raul SK et al (2016) Loss of CHD1 causes DNA repair defects and enhances prostate cancer therapeutic responsiveness. EMBO Rep 17:1609\u20131623. https:\/\/doi.org\/10.15252\/embr.201642352","journal-title":"EMBO Rep"},{"key":"10536_CR59","doi-asserted-by":"publisher","first-page":"4836","DOI":"10.1158\/1078-0432.CCR-21-0121","volume":"27","author":"C Calagua","year":"2021","unstructured":"Calagua C, Ficial M, Jansen CS et al (2021) A subset of localized prostate Cancer displays an Immunogenic phenotype associated with losses of key tumor suppressor genes. Clin Cancer Res Off J Am Assoc Cancer Res 27:4836\u20134847. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-0121","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"10536_CR60","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/s11060-019-03099-x","volume":"142","author":"DR Ormond","year":"2019","unstructured":"Ormond DR, Kleinschmidt-DeMasters BK, Cavalcante D et al (2019) Prostatic adenocarcinoma CNS parenchymal and dural metastases: alterations in ERG, CHD1 and MAP3K7 expression. J Neurooncol 142:319\u2013325. https:\/\/doi.org\/10.1007\/s11060-019-03099-x","journal-title":"J Neurooncol"},{"key":"10536_CR61","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1016\/j.jmoldx.2020.02.012","volume":"22","author":"SR Rao","year":"2020","unstructured":"Rao SR, Alham NK, Upton E et al (2020) Detailed molecular and immune marker profiling of archival prostate Cancer samples reveals an inverse association between TMPRSS2:ERG fusion status and immune cell infiltration. J Mol Diagn JMD 22:652\u2013669. https:\/\/doi.org\/10.1016\/j.jmoldx.2020.02.012","journal-title":"J Mol Diagn JMD"},{"key":"10536_CR62","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1158\/1541-7786.MCR-20-0913","volume":"19","author":"LK Jillson","year":"2021","unstructured":"Jillson LK, Rider LC, Rodrigues LU et al (2021) MAP3K7 loss drives enhanced androgen signaling and independently confers risk of recurrence in prostate Cancer with joint loss of CHD1. Mol Cancer Res MCR 19:1123\u20131136. https:\/\/doi.org\/10.1158\/1541-7786.MCR-20-0913","journal-title":"Mol Cancer Res MCR"},{"key":"10536_CR63","doi-asserted-by":"publisher","first-page":"e0254697","DOI":"10.1371\/journal.pone.0254697","volume":"16","author":"AE Roehrig","year":"2021","unstructured":"Roehrig AE, Klupsch K, Oses-Prieto JA et al (2021) Cell-cell adhesion regulates Merlin\/NF2 interaction with the PAF complex. PLoS ONE 16:e0254697. https:\/\/doi.org\/10.1371\/journal.pone.0254697","journal-title":"PLoS ONE"},{"key":"10536_CR64","doi-asserted-by":"publisher","first-page":"963007","DOI":"10.3389\/fonc.2022.963007","volume":"12","author":"M Shen","year":"2022","unstructured":"Shen M, Demers L-K, Bailey SD, Labb\u00e9 DP (2022) To bind or not to bind: cistromic reprogramming in prostate cancer. Front Oncol 12:963007. https:\/\/doi.org\/10.3389\/fonc.2022.963007","journal-title":"Front Oncol"},{"key":"10536_CR65","doi-asserted-by":"publisher","first-page":"416","DOI":"10.3390\/cancers14020416","volume":"14","author":"M K\u00f6bel","year":"2022","unstructured":"K\u00f6bel M, Kang EY (2022) The evolution of ovarian carcinoma subclassification. Cancers 14:416. https:\/\/doi.org\/10.3390\/cancers14020416","journal-title":"Cancers"},{"key":"10536_CR66","doi-asserted-by":"publisher","first-page":"952","DOI":"10.3390\/ijms20040952","volume":"20","author":"M-A Lisio","year":"2019","unstructured":"Lisio M-A, Fu L, Goyeneche A et al (2019) High-Grade serous ovarian cancer: basic sciences, clinical and therapeutic standpoints. Int J Mol Sci 20:952. https:\/\/doi.org\/10.3390\/ijms20040952","journal-title":"Int J Mol Sci"},{"key":"10536_CR67","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1158\/0008-5472.CAN-14-1596","volume":"75","author":"LU Rodrigues","year":"2015","unstructured":"Rodrigues LU, Rider L, Nieto C et al (2015) Coordinate loss of MAP3K7 and CHD1 promotes aggressive prostate cancer. Cancer Res 75:1021\u20131034. https:\/\/doi.org\/10.1158\/0008-5472.CAN-14-1596","journal-title":"Cancer Res"},{"key":"10536_CR68","doi-asserted-by":"publisher","first-page":"13670","DOI":"10.3390\/ijms232213670","volume":"23","author":"I Vaicekauskait\u0117","year":"2022","unstructured":"Vaicekauskait\u0117 I, Sabaliauskait\u0117 R, Lazutka JR, Jarmalait\u0117 S (2022) The emerging role of chromatin remodeling complexes in ovarian Cancer. Int J Mol Sci 23:13670. https:\/\/doi.org\/10.3390\/ijms232213670","journal-title":"Int J Mol Sci"},{"key":"10536_CR69","doi-asserted-by":"publisher","first-page":"12815","DOI":"10.3390\/ijms232112815","volume":"23","author":"F-L Zhang","year":"2022","unstructured":"Zhang F-L, Li D-Q (2022) Targeting Chromatin-Remodeling factors in Cancer cells: promising molecules in Cancer therapy. Int J Mol Sci 23:12815. https:\/\/doi.org\/10.3390\/ijms232112815","journal-title":"Int J Mol Sci"},{"key":"10536_CR70","doi-asserted-by":"publisher","first-page":"381","DOI":"10.2217\/epi.14.31","volume":"6","author":"W Li","year":"2014","unstructured":"Li W, Mills AA (2014) Architects of the genome: CHD dysfunction in cancer, developmental disorders and neurological syndromes. Epigenomics 6:381\u2013395. https:\/\/doi.org\/10.2217\/epi.14.31","journal-title":"Epigenomics"},{"key":"10536_CR71","doi-asserted-by":"publisher","first-page":"448","DOI":"10.3390\/cancers15020448","volume":"15","author":"M Ovejero-S\u00e1nchez","year":"2023","unstructured":"Ovejero-S\u00e1nchez M, Gonz\u00e1lez-Sarmiento R, Herrero AB (2023) DNA damage response alterations in ovarian cancer: from molecular mechanisms to therapeutic opportunities. Cancers 15:448. https:\/\/doi.org\/10.3390\/cancers15020448","journal-title":"Cancers"},{"key":"10536_CR72","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s13578-023-00953-4","volume":"13","author":"D Jiang","year":"2023","unstructured":"Jiang D, Li T, Guo C et al (2023) Small molecule modulators of chromatin remodeling: from neurodevelopment to neurodegeneration. Cell Biosci 13:10. https:\/\/doi.org\/10.1186\/s13578-023-00953-4","journal-title":"Cell Biosci"},{"key":"10536_CR73","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.3390\/cancers15061897","volume":"15","author":"MS Gillespie","year":"2023","unstructured":"Gillespie MS, Ward CM, Davies CC (2023) DNA repair and therapeutic strategies in Cancer stem cells. Cancers 15:1897. https:\/\/doi.org\/10.3390\/cancers15061897","journal-title":"Cancers"},{"key":"10536_CR74","doi-asserted-by":"publisher","unstructured":"Xie H, Jin W, Xia B (2021) Targeting DNA repair response promotes immunotherapy in ovarian cancer: rationale and clinical application. Front Immunol 12. https:\/\/doi.org\/10.3389\/fimmu.2021.661115","DOI":"10.3389\/fimmu.2021.661115"},{"key":"10536_CR75","doi-asserted-by":"publisher","first-page":"225","DOI":"10.3390\/genes16020225","volume":"16","author":"K Goswami","year":"2025","unstructured":"Goswami K, Venkatachalam K, Singh SP et al (2025) Chromatin remodulator CHD4: A potential target for Cancer interception. Genes 16:225. https:\/\/doi.org\/10.3390\/genes16020225","journal-title":"Genes"},{"key":"10536_CR76","doi-asserted-by":"publisher","first-page":"101821","DOI":"10.1016\/j.tranon.2023.101821","volume":"39","author":"HQ Sadida","year":"2023","unstructured":"Sadida HQ, Abdulla A, Marzooqi SA et al (2023) Epigenetic modifications: key players in cancer heterogeneity and drug resistance. Transl Oncol 39:101821. https:\/\/doi.org\/10.1016\/j.tranon.2023.101821","journal-title":"Transl Oncol"},{"key":"10536_CR77","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s13045-023-01431-7","volume":"16","author":"T Zhang","year":"2023","unstructured":"Zhang T, Auer P, Dong J et al (2023) Whole-genome sequencing identifies novel predictors for hematopoietic cell transplant outcomes for patients with myelodysplastic syndrome: a CIBMTR study. J Hematol OncolJ Hematol Oncol 16:37. https:\/\/doi.org\/10.1186\/s13045-023-01431-7","journal-title":"J Hematol OncolJ Hematol Oncol"},{"key":"10536_CR78","doi-asserted-by":"publisher","first-page":"3681","DOI":"10.1182\/blood-2021-153344","volume":"138","author":"T Zhang","year":"2021","unstructured":"Zhang T, Auer P, Spellman SR et al (2021) Identification of novel prognostic biomarkers DDX11 and CHD1 of allogeneic hematopoietic cell transplantation outcomes for patients with MDS: A CIBMTR comprehensive genomic screening. Blood 138:3681. https:\/\/doi.org\/10.1182\/blood-2021-153344","journal-title":"Blood"},{"key":"10536_CR79","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/1756-8935-8-4","volume":"8","author":"L Siggens","year":"2015","unstructured":"Siggens L, Cordeddu L, R\u00f6nnerblad M et al (2015) Transcription-coupled recruitment of human CHD1 and CHD2 influences chromatin accessibility and histone H3 and H3.3 occupancy at active chromatin regions. Epigenetics Chromatin 8:4. https:\/\/doi.org\/10.1186\/1756-8935-8-4","journal-title":"Epigenetics Chromatin"},{"key":"10536_CR80","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s12943-015-0353-x","volume":"14","author":"H Yao","year":"2015","unstructured":"Yao H, Pan J, Wu C et al (2015) Transcriptome sequencing reveals CHD1 as a novel fusion partner of RUNX1 in acute myeloid leukemia with t(5;21)(q21;q22). Mol Cancer 14:81. https:\/\/doi.org\/10.1186\/s12943-015-0353-x","journal-title":"Mol Cancer"},{"key":"10536_CR81","doi-asserted-by":"publisher","first-page":"194","DOI":"10.4251\/wjgo.v9.i5.194","volume":"9","author":"SK Garattini","year":"2017","unstructured":"Garattini SK, Basile D, Cattaneo M et al (2017) Molecular classifications of gastric cancers: novel insights and possible future applications. World J Gastrointest Oncol 9:194\u2013208. https:\/\/doi.org\/10.4251\/wjgo.v9.i5.194","journal-title":"World J Gastrointest Oncol"},{"key":"10536_CR82","doi-asserted-by":"publisher","first-page":"4441","DOI":"10.1158\/1078-0432.CCR-16-2211","volume":"23","author":"BH Sohn","year":"2017","unstructured":"Sohn BH, Hwang J-E, Jang H-J et al (2017) Clinical significance of four molecular subtypes of gastric cancer identified by the Cancer genome atlas project. Clin Cancer Res Off J Am Assoc Cancer Res 23:4441\u20134449. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-2211","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"10536_CR83","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.4161\/epi.6.11.17744","volume":"6","author":"X Xu","year":"2011","unstructured":"Xu X, Gammon MD, Jefferson E et al (2011) The influence of one-carbon metabolism on gene promoter methylation in a population-based breast cancer study. Epigenetics 6:1276\u20131283. https:\/\/doi.org\/10.4161\/epi.6.11.17744","journal-title":"Epigenetics"},{"key":"10536_CR84","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1007\/s12253-019-00658-5","volume":"26","author":"Z Li","year":"2020","unstructured":"Li Z, Guo Z (2020) Comparison of CDH1 gene hypermethylation status in blood and serum among gastric Cancer patients. Pathol Oncol Res POR 26:1057\u20131062. https:\/\/doi.org\/10.1007\/s12253-019-00658-5","journal-title":"Pathol Oncol Res POR"},{"key":"10536_CR85","doi-asserted-by":"publisher","first-page":"310","DOI":"10.15386\/mpr-2570","volume":"96","author":"O Aghiorghiesei","year":"2023","unstructured":"Aghiorghiesei O, Irimie AI, Braicu C et al (2023) Epigenetic methylation changes: implication as biomarkers in oral and maxillofacial area cancers. Med Pharm Rep 96:310\u2013317. https:\/\/doi.org\/10.15386\/mpr-2570","journal-title":"Med Pharm Rep"},{"key":"10536_CR86","doi-asserted-by":"publisher","first-page":"e12700","DOI":"10.1111\/cpr.12700","volume":"53","author":"J Zhu","year":"2019","unstructured":"Zhu J, Gu W, Yu C (2019) MATN1-AS1 promotes glioma progression by functioning as CeRNA of miR\u2010200b\/c\/429 to regulate CHD1 expression. Cell Prolif 53:e12700. https:\/\/doi.org\/10.1111\/cpr.12700","journal-title":"Cell Prolif"},{"key":"10536_CR87","doi-asserted-by":"publisher","first-page":"5163","DOI":"10.1007\/s12035-021-02474-y","volume":"58","author":"J Chen","year":"2021","unstructured":"Chen J, Wang H, Wang J et al (2021) LncRNA NEAT1 enhances glioma progression via regulating the miR-128-3p\/ITGA5 Axis. Mol Neurobiol 58:5163\u20135177. https:\/\/doi.org\/10.1007\/s12035-021-02474-y","journal-title":"Mol Neurobiol"},{"key":"10536_CR88","doi-asserted-by":"publisher","first-page":"590033","DOI":"10.3389\/fonc.2020.590033","volume":"10","author":"M Capasso","year":"2020","unstructured":"Capasso M, Montella A, Tirelli M et al (2020) Genetic predisposition to solid pediatric cancers. Front Oncol 10:590033. https:\/\/doi.org\/10.3389\/fonc.2020.590033","journal-title":"Front Oncol"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-025-10536-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-025-10536-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-025-10536-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,27]],"date-time":"2025-12-27T16:24:37Z","timestamp":1766852677000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-025-10536-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,25]]},"references-count":88,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["10536"],"URL":"https:\/\/doi.org\/10.1007\/s11033-025-10536-w","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,25]]},"assertion":[{"value":"5 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"426"}}